RB1 and plasma cell myeloma: Furthermore, analysis of patients with MM at different disease stages, from initial diagnosis to end-stage secondary plasmacytic leukemia (sPCL), demonstrated that RB1 and ZKSCAN3 mutations emerged exclusively in the final sPCL samples, suggesting a role of RB1 in both myeloma initiation and extramedullary infiltration (44).